The study of aromatic antiepileptic drug-induced skin adverse reactions and HLA alleles

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900024842

Enrollment

Unknown

Registered

2019-07-30

Start date

2019-01-30

Completion date

Unknown

Last updated

2019-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

epilepsy

Interventions

Adverse skin reactions to aromatic antiepileptics group:HLA gene testing

No adverse skin reactions to aromatic antiepileptic drugs group:HLA gene testing

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) the patient was clearly diagnosed as epileptic; (2) the patient was taking some aromatic antiepileptic drugs for the first time; (3) the patient signed the informed consent.

Exclusion criteria

Exclusion criteria: (1) the patients took aromatic antiepileptics for less than 3 months, and the reason for discontinuation was not due to adverse skin reactions caused by aromatic antiepileptics; (2) the patients were added with another or more aromatic antiepileptics during follow-up; (3) the patients were lost to follow-up.

Design outcomes

Primary

Measure	Time frame
HLA genotyping;Classification of skin adverse reactions;The dose of the drug when adverse skin reactions occur;Length of time from initiation of this aromatic antiepileptic drug to the occurrence of adverse skin reactions;	—

Contacts

Public ContactZou Xiaoyi

West China Hospital, Sichuan University

xiaoyizou@163.com+86 18980602115

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026